The House Energy and Commerce Subcommittee on Health today held a hearing to discuss four bills aimed at making prescription drugs more affordable for Americans. “It is time for Congress to take bold and decisive action to reduce prescription drug prices for all Americans,” said Energy and Commerce Committee Chairman Frank Pallone, D-N.J. Among other bills, the subcommittee discussed the Lower Drug Costs Now Act of 2019 (H.R. 3). Introduced last week by House Democratic leaders, the bill would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs, including allowing the Department of Health and Human Services to negotiate directly with drug manufacturers the price of at least 25 — and up to 250 — brand-name prescription drugs that lack price competition in the market. Witnesses at the hearing were from Baldwin Wallace University, Johns Hopkins Bloomberg School of Public Health and American Enterprise Institute.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention Friday released an update to its 1998 guidelines to prevent and control infection in the health care workplace,…
Headline
The House Energy and Commerce Committee last night approved a revised version of the Lower Prescription Drug Costs Now Act.
Headline
Two House committees today marked up revised versions of the Lower Prescription Drug Costs Now Act (H.R. 3) — legislation that would make a series of changes…
Headline
The average launch prices for new brand-name drugs and new generic drugs have skyrocketed since 2006, according to an analysis from 46brooklyn.
Headline
Congress should pass legislation that protects patients from surprise medical bills and rejects rate setting, hospital leaders said today at an AHA briefing on…
Headline
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases…